دورية أكاديمية
First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
العنوان: | First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study. |
---|---|
المؤلفون: | Voss, Martin H, Gurney, Howard, Atduev, Vagif, Suárez, Cristina, Climent, Miguel Ángel, Pook, David William, Tomczak, Piotr, Barthelemy, Philippe, Lee, Jae-Lyun, Nalbandian, Taron, Stus, Viktor, Ferguson, Thomas, Wiechno, Pawel, Gokmen, Erhan, Lacombe, Louis, Gedye, Craig, Burgents, Joseph E., Sharma, Manish, Cornell, Jerry, Albiges, Laurence |
المصدر: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p2-2, 5p |
قاعدة البيانات: | Supplemental Index |
كن أول من يترك تعليقا!